Mepolizumab [196078-29-2]

Biological Activity

Mepolizumab (SB 240563) is a humanized monoclonal antibody that binds to and neutralizes interleukin-5 (IL-5), the major cytokine involved in eosinophil proliferation, activation, and survival. Mepolizumab can be used for the research of eosinophilic granulomatosis with polyangiitis (EGPA) and severe eosinophilic asthma.

Chemical Information

CAS Number	196078-29-2
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] David Charles, et al. Clin Exp Allergy. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis

[2] Ian D Pavord, et al. Allergy. From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases

[3] Ioana Agache, et al. Allergy. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

[4] Michael E Wechsler, et al. N Engl J Med. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis